253 related articles for article (PubMed ID: 33054113)
1. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.
Garbowski MW; Bansal S; Porter JB; Mori C; Burckhardt S; Hider RC
Haematologica; 2021 Nov; 106(11):2885-2896. PubMed ID: 33054113
[TBL] [Abstract][Full Text] [Related]
2. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Diebold M; Kistler AD
BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
5. Impact of oral iron challenges on circulating non-transferrin-bound iron in healthy Guatemalan males.
Schümann K; Kroll S; Romero-Abal ME; Georgiou NA; Marx JJ; Weiss G; Solomons NW
Ann Nutr Metab; 2012; 60(2):98-107. PubMed ID: 22398912
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
7. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.
Koskenkorva-Frank TS; Weiss G; Koppenol WH; Burckhardt S
Free Radic Biol Med; 2013 Dec; 65():1174-1194. PubMed ID: 24036104
[TBL] [Abstract][Full Text] [Related]
8. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
9. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
10. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
Scheiber-Mojdehkar B; Lutzky B; Schaufler R; Sturm B; Goldenberg H
J Am Soc Nephrol; 2004 Jun; 15(6):1648-55. PubMed ID: 15153577
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of non-transferrin-bound and transferring-bound iron uptake in primary hippocampal neurons.
Ji C; Kosman DJ
J Neurochem; 2015 Jun; 133(5):668-83. PubMed ID: 25649872
[TBL] [Abstract][Full Text] [Related]
13. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients.
Malone M; Barish C; He A; Bregman D
Obes Surg; 2013 Sep; 23(9):1413-20. PubMed ID: 23553506
[TBL] [Abstract][Full Text] [Related]
14. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT).
Hilken A; Langebrake C; Wolschke C; Kersten JF; Rohde H; Nielsen P; Kröger N
Ann Hematol; 2017 Aug; 96(8):1379-1388. PubMed ID: 28585071
[TBL] [Abstract][Full Text] [Related]
15. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
17. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials.
Shi L; Zhao Y; Rao A
Afr Health Sci; 2023 Sep; 23(3):205-212. PubMed ID: 38357109
[TBL] [Abstract][Full Text] [Related]
18. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
[TBL] [Abstract][Full Text] [Related]
20. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.
Zheng H; Huang X; Zhang Q; Katz SD
Kidney Int; 2006 Feb; 69(4):679-84. PubMed ID: 16395269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
